Compare Novartis AG (NVS) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs ABRDN Physical Gold Shares ETF — how do they compare? Novartis AG trades at $154.71 (market cap $295.37B), while ABRDN Physical Gold Shares ETF trades at $41.87. The key difference: Novartis AG pays a 3.07% dividend while ABRDN Physical Gold Shares ETF pays none, and Novartis AG is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| NVS | SGOL | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $168.62 | $51.41 |
52-Week Low | $119.31 | $31.61 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
SGOL trades at $42.03, up 0.55% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent gold price strength is driven by cooling U.S. inflation data and central bank demand, as spot gold surpassed $4,430/oz following July CPI data (Kitco, 2026-08-12). The stock lacks disclosed financial ratios, limiting fundamental analysis.
Outlook remains positive near-term due to gold's momentum, but high RSI suggests potential pullback risks. Investment appeal hinges on gold's macro trends; key risks include Fed policy shifts and dollar volatility. Analyst sentiment is mixed with technical indicators signaling caution despite bullish price action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
